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Objectives: Differentiating sepsis from other noninfectious causes of systemic inﬂammatory response
syndrome (SIRS) in cancer patients is often challenging. Although lactate and procalcitonin have been
studied extensively regarding sepsis management, little is known about their utility in cancer patients.
This study aimed to compare the diagnostic and prognostic utility of lactate and procalcitonin for sepsis
in cancer patients.
Material and methods: This prospective case-control study was conducted with adult cancer patients
presenting to emergency department (ED) with at least two SIRS criteria. The infection status of each
patient was determined retrospectively.
Main diagnostic variables were calculated for diagnostic and prognostic utilities of lactate and
procalcitonin.
Results: Among 86 patients, mean age was 61. Twenty-two (25.6%) were determined in the sepsis group.
In the ROC analysis, a lactate value of 1 mmol/L predicted sepsis with 86.36% (95%CI: 65.1%e97.1%)
sensitivity and 28.12% (95%CI: 17.6%e40.76%) speciﬁcity. A procalcitonin value of 0.8 ng/mL yielded a
sensitivity of 63.64% (95%CI: 40.7%e82.8%) and 76.56% (95%CI: 63.4%e86.2%) speciﬁcity for differential
diagnosis of sepsis in cancer patients.
Lactate and procalcitonin showed similar abilities in differentiating sepsis from non-infective SIRS in
cancer patients [AUROCs of 0.638 (95%CI:0.527e0.739) vs 0.637 (95%CI:0.527e0.738), respectively.
p¼ 0.994].
They were also similar in predicting poor clinical outcome with AUROCs of 0.629 (95%CI:0.518e0.731)
and 0.584 (95%CI: 0.473e0.69), respectively (p¼ 0.577).
Conclusions: The results of this study indicated that, none of the lactate and procalcitonin can be rec-
ommended alone to differentiate sepsis from non-infectious SIRS and to predict the poor clinical out-
comes in adult cancer patients with SIRS in the ED.
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sepsis is deﬁned as the presence of probable or documented
infection together with systemic inﬂammatory response syndrome
(SIRS).1 Early diagnosis of sepsis and timely initiation of evidence-kultesi Acil Tıp ABD, 41300,
1, þ90 5055251926 (mobile).
a).
ncy Medicine Association of
e Association of Turkey. Production
ons.org/licenses/by-nc-nd/4.0/).based treatment strategies are known to improve the clinical out-
comes and to reduce sepsis-related mortality.1,2
The emergency department (ED) is a frequent ﬁrst point of
contact for cancer patients. Cancer patients are ten times more
likely to develop sepsis since they are immunocompromised. In
addition to be the most common comorbidity in septic patients,
cancer is the highest risk factor for mortality in sepsis.3 Early
diagnosis of sepsis and distinguishing it from noninfectious pro-
cesses are of paramount importance to initiate an appropriate
treatment on time in these patients.4 Besides its low speciﬁcity, theand hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
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distinction challenging for emergency physicians.5,6 A biomarker
can be very helpful in the appropriate management of these pa-
tients in the ED andmay help to avoid unnecessary diagnostic tests,
hospitalization, and unwarranted antimicrobial therapy.
There have been sufﬁcient studies on diagnosis and prediction
of severity for procalcitonin and lactate sepsis.7,8 However, little is
known about their utility in cancer patients.9
The aim of this study was to compare diagnostic and prognostic
values of lactate and procalcitonin levels for sepsis in cancer pa-
tients presenting to ED with SIRS.
2. Materials and methods
2.1. Design and setting
This prospective case-control studywas conducted in the ED of a
teaching hospital in XXXX, Turkey between February 2014 and
August 2014. Institutional ethics committee approval (Project
Number: XXXX 2014/45) and written informed consent of patients
were obtained.
The study site is a tertiary hospital in which about 2000 cancer
patients receive care per year. The ED provides care for about
40,000 patients annually. An average of 10% of the ED patients is
cancer patients.
2.2. Participants
The study group was composed of adult cancer patients who
met at least two of the SIRS criteria presented to ED at times in
which the principal investigator (EK) was accessible. Exclusion
criteria were hematologic and thyroid malignancies, liver
dysfunction, trauma patients, patients who presented to the ED
because of seizure or missing data for follow-up. In addition, pa-
tients who were treated with intravenous ﬂuid therapy of more
than 500cc when they were determined as candidates for study,
patients whose blood was obtained for lactate and procalcitonin
levels, patients using antibiotics at presentation, or those receiving
parenteral ﬂuid therapy at home were also excluded.
2.3. Protocol
All cancer patients whomet the inclusion criteria were recorded
regardless of the complaint. Blood samples were taken for lactate
and procalcitonin levels immediately, at the time that patients were
identiﬁed to be eligible for the study. The procalcitonin levels were
studied bedside using an immunoassay method and detected by an
i-CHROMA Reader (Boditech Med. Inc., KOREA, 2013) device.
For procalcitonin levels, 2 cc blood taken into a mere vacuum
tube was centrifuged for 10 min at 4000 rpm, then serum of 150 mL
was taken and aliquoted into 1.5 mL tubes. An aliquot of 75 mL was
used for the procalcitonin kit. After waiting 12 min, it was pro-
cessed in the device and results were obtained in 5 s. The limits of
detection were indicated as 0.25e100 ng/mL. The procalcitonin
level of greater than 0.5 ng/ml was accepted as probable infection,
and the level of greater than 10.0 ng/mL was accepted as severe
sepsis or septic shock according to the manufacture protocol.
Lactate levels from radial artery blood administered to a heparin
syringe of 2.5 cc was sent to the emergency laboratory pneumati-
cally, followed by analysis with an electrode method by blind
technicians using Radiometer ABL 700 Copenhagen (Denmark,
2012) device. The results of lactate levels were obtained as mg/dl,
and were converted into mmol/L by multiplying by the constant
‘0.111’ in order to compare with literature.The presentation characteristics of patients, radiology and lab-
oratory results data with emergency management, lactate levels,
and ED outcomes were recorded by the caregiver emergency
physician. These doctors were unaware of the procalcitonin levels.
However, lactate levels were used in patient care without any
changes speciﬁc to this study. Hospital database and phone con-
tacts by the principal investigator with patients or their relatives
were used for a 28-day follow-up. In addition, radiographic and
laboratory data in the form of data were checked from the medical
records and ED charts.
Patients whose probable cause of SIRS were assumed to be
infection and had been veriﬁed clinically infected were accepted as
sepsis. In this study, the presence of infection was decided by the
lead investigator retrospectively with clinical evidence, laboratory
ﬁndings, and imaging results based on the criteria of “International
Sepsis Forum Consensus Conference on Deﬁnitions of Infection”.10
All inpatient and outpatient follow-up data were reviewed for ev-
idence or probability of infection as deﬁned by the consensus.
Those for whom infection had not been considered or shown were
determined as the ‘sepsis negative group’. Intensive care unit (ICU)
requirements or mortality were considered as “poor clinical
outcome”.
2.4. Outcome measures
The primary outcome was the detection of sepsis with lactate
and procalcitonin levels. The secondary outcome was the compar-
ison of utility of the biomarkers for predicting poor clinical
outcomes.
2.5. Statistical analysis
Statistical analyses were performed using MedCalc for Win-
dows, version 13.1.0.0 (MedCalc Software, Ostend, Belgium). All
continuous variables were presented with 95% conﬁdence intervals
(CI). Categorical variables were expressed as percentages or ratios.
Independent samples t-test or Mann Whitney U test were used
in the comparison of continuous variables between groups. Chi-
square or Fisher's exact test were used in the comparison of cate-
gorical variables between groups where appropriate.
Sensitivity, speciﬁcity, positive and negative likelihood ratios
(LRs) of markers at potential and determined thresholds were
calculated with 95% CI. Diagnostic and prognostic performances of
markers were assessed with Receiver operating characteristic
(ROC) curve analysis. The area-under-the-curve (AUC) comparisons
were conducted with nonparametric DeLong method which is used
in the comparison of ROC curves of tests performed on the same
individual. A p-value of 0.05 was considered statistically signiﬁcant.
3. Results
Among 94 eligible patients, 86 were included in the study
(Fig. 1). The median age of was 61 (95% CI: 58e64). The most
common malignancy in this study was lung cancer. However,
cancer stage data of half of the patients could not be achieved. A
total of 39 patients (45.3%) had no comorbid diseases in the study
group. The demographic and clinical characteristics are presented
in Table 1.
Infection foci considered by the caregiver physician of patients
were as follows: lung (n¼ 16), bladder (n¼ 6), gallbladder (n¼ 2),
bowel (n¼ 2), tonsils (n¼ 1), and ear (n¼ 1). A total of 6 out of
those (lung-4, bladder-1, bowel-1) were assessed as sepsis negative
since it was not supported by clinical, laboratory, and radiological
evidences in the retrospective evaluation. As a result, sepsis was
observed in 22 (25.6%) of patients in the study group. There was a
Fig. 1. Patient ﬂow chart.
Table 1
Demographic and clinical characteristics of patients in the study.
Variable Total (N¼ 86)
AGE (mean/median) (95% CI) 61 (54-69)
Gender (n, %)
Female 27 (31.4)
Male 59 (68.6)
Cancer type (n, %)
Lung 35 (40.7)
Breast 8 (9.3)
Genitourinary 7 (8.1)
Gastrointestinal 20 (23.3)
Female genital 5 (5.8)
Male genital 3 (3.5)
Airway 3 (3.5)
Brain 2 (2.3)
Other 3 (3.5)
Cancer stage (n, %)
Unknown 48 (55.8)
Stage 1 5 (5.8)
Stage 2 3 (3.4)
Stage 3 1 (1.1)
Stage 4 29 (33.7)
Comorbidity (n, %)
No 39 (45.4)
DM 14 (16.2)
HT 27 (31.3)
COPD 10 (11.6)
CHF 8 (9.3)
CRF 3 (3.4)
Other 2 (2.3)
Last CT time (n, %)
Not receiving 16 (18.6)
Unknown 13 (15.1)
Last 2 weeks 20 (23.2)
2e4 weeks 11 (12.7)
>1 month 26 (30.2)
Presentation Complaints (n, %)
Shortness of breath 32 (37.2)
Fatigue 11 (12.7)
Fever 7 (8.1)
Abdominal pain 7 (8.1)
General condition disorder 6 (7.0)
Pain 6 (7.0)
Inability of nutrition 6 (7.0)
Hemoptysis 4 (4.7)
Inability to urinate 3 (3.5)
Other 4 (4.7)
DM: Diabetes mellitus; HT: Hypertension; COPD: Chronic obstructive pulmonary diseas
conﬁdence interval.
E. Keçe et al. / Turkish Journal of Emergency Medicine 16 (2016) 1e7 3statistically signiﬁcant difference in only themean PaCO2 andmean
WBC between groups when SIRS criteria were examined (Table 2).
Therewas no signiﬁcant difference between groups according to
sepsis diagnosis in emergency laboratory data including glucose,
BUN, creatinine, albumin, AST, ALT, Calcium, Hb, CRP, and the base
deﬁcit.
Median lactate levels were found to be similar between the
sepsis negative group (median: 1.67 mmol/L, 95% CI: 1.33e1.78)
and sepsis positive group (median: 1.89 mmol/L, 95% CI: 1.55e3.46)
(p¼ 0.054). Serum procalcitonin levels were signiﬁcantly higher in
the sepsis group (median: 1.01 ng/mL, 95% CI: 0.25e2.48)
compared to the sepsis negative group (median: 0.25 ng/mL, 95%
CI: 0.25e0.80) (p ¼ 0.042). Two patients, whose procalcitonin
levels were measured 100 ng/ml, were in sepsis negative group and
one of them died in the follow-up.3.1. Diagnostic utility
In the ROC curve analysis, sensitivity was 36.36% (95% CI: 17.2%e
59.3%), speciﬁcity was 90.62% (95% CI: 80.7%e96.5%), positive LRSepsis () (n¼ 64) Sepsis (þ) (n¼ 22)
63 (58.7e65.3) 60 (54.8e64)
23 (35.9) 4 (18.2)
41 (64.1) 18 (81.8)
27 (42.2) 8 (36.4)
6 (9.4) 2 (9.1)
4 (6.3) 3 (13.6)
15 (23.4) 5 (22.7)
5 (7.8) 0
2 (3.1) 1 (4.5)
2 (3.1) 1 (4.5)
1 (1.6) 1 (4.5)
2 (3.1) 1 (4.5)
36 (56.2) 12 (54.6)
2 (3.1) 3 (13.6)
3 (4.7) 0
1 (1.6) 0
22 (34.4) 7 (31.8)
30 (46.9) 9 (40.9)
12 (18.8) 2 (9.1)
19 (29.7) 8 (36.4)
9 (14.1) 1 (4.5)
6 (9.4) 2 (9.1)
0 3 (13.6)
1 (1.6) 1 (4.5)
11 (17.2) 5 (22.7)
9 (14.1) 4 (18.2)
18 (28.1) 2 (9.1)
9 (14.1) 2 (9.1)
17 (26.5) 9 (40.9)
23 (35.9) 9 (40.9)
10 (15.6) 1 (4.5)
4 (6.3) 3 (13.6)
6 (9.4) 1 (4.5)
6 (9.4) 0
2 (3.1) 4 (18.2)
5 (7.8) 1 (4.5)
3 (4.7) 1 (4.5)
2 (3.1) 1 (4.5)
3 (4.7) 1 (4.5)
e; CHF: Congestive heart failure; CRF: Chronic renal failure; CT: Chemotherapy; CI:
Table 2
The mean values of SIRS criteria in groups.
Variable Total
N: 86
Sepsis ()
n: 64
Sepsis (þ)
n: 22
p Value
Pulse rate (beats/min) [mean (95% CI)] 115.5 (110.9e120.1) 114.0 (108.4e119.6) 119.8 (112.1e127.5) 0.278a
Temperature (C) [mean (95% CI)] 36.5 (36.2e36.7) 36.5 (36.3e36.8) 36.4 (35.8e37.0) 0.710a
Respiratory rate/min [median (95% CI)] 26.0 (24.4e28.0) 25.5 (24.0e28.0) 28.0 (25.0e32.0) 0.241b
PaCO2(mmHg) [median (95% CI)] 33.8 (32.0e35.3) 35.0 (33.1e37.0) 30.5 (27.2e33.0) 0.005b
WBC(103/uL) [mean (95% CI)] 11.1 (9.1e13.0) 8.7 (6.4e9.8) 17.9 (12.2e23.5) 0.003a
WBC: White blood cell; paCO2: partial carbon dioxide pressure; SD: standard deviation; CI: conﬁdence interval.
a Provided via t-test.
b Provided via ManneWhitney U test.
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cutoff value of lactate set at 2.98 mmol/L in diagnosis of sepsis
patients. The analysis demonstrated an AUC of 0.638 (95% CI:
0.527e0.739) (p ¼ 0.061) for lactate to diagnose sepsis.
With regard to sepsis diagnosis, for a level of 0.8 ng/mL, pro-
calcitonin provided a sensitivity of 63.64% (95% CI: 40.7%e82.8%)
and a speciﬁcity of 76.56% (95% CI: 64.3%e86.2%) and a positive LR
of 2.72 (95% CI: 1.9e3.8) with a negative LR of 0.47 (95% CI: 0.2e1).
The AUC was 0.637 (95% CI: 0.527e0.738) (p ¼ 0.0496).
For sepsis diagnosis, the comparison of ROC curves with DeLong
method revealed a difference of 0.00071 (95% CI: 0.178e0.180)
between AUCs of lactate and procalcitonin (Fig. 2).
The diagnostic values of lactate and procalcitonin levels at the
potential cutoffs are presented in Table 3.
A total of 49 patients (57.0%) in study group were discharged
upon the completion of emergency care. A total of 32 patients
(37.2%) out of remaining 37 were hospitalized in the wards and 5
(5.8%) were hospitalized in the ICU. At the end of twenty-eight days
follow-up, 49 (57%) patients did not suffer poor clinical outcomes
while, 21 (24.4%) ICU requirements and 32 (37.2%) mortalities were
observed. There was no signiﬁcant relationship between poor
clinical outcomes and sepsis diagnosis (p ¼ 0.816). Mortality was
not associated with the presence of sepsis either (p ¼ 0.544).3.2. Prognostic utility
The 28-day mortality prediction abilities of lactate and pro-
calcitonin were found to be similar and insufﬁcient. The AUC wasFig. 2. The comparison of ROC curves of serum lactate and procalcitonin levels in
sepsis diagnosis.0.676 (95% CI: 0.566e0.733) for lactate and 0.548 (95% CI:
0.437e0.655) for procalcitonin (p ¼ 0.099).
In the prediction of poor clinical outcomes including mortality
or ICU requirements, sensitivity was 51.35% (95% CI: 34.4%e68.1%),
speciﬁcity was 81.63% (95% CI: 68%e91.2%), positive LRwas 2.8 (95%
CI: 2e3.9), and negative LR was 0.6 (95% CI: 0.3e1.2) for lactate
value of 1.89mmol/L. The AUCwas 0.629 (95% CI: 0.518e0.731). At a
cutoff value of procalcitonin set at 2.47 ng/mL based on the ROC
curve's optimal threshold the sensitivity, speciﬁcity, positive and
negative LR were 29.73% (95% CI: 15.9%e47%), 91.84% (95% CI:
80.4%e97.7%), 3.64 (95% CI: 2.2e6) and 0.77 (95% CI: 0.3e2),
respectively, for predicting poor clinical outcomes. The AUC was
found 0.584 (95% CI: 0.473e0.69) for procalcitonin. The ROC curve
comparison showed 0.0444 (95% CI: 0.112e0.2) difference be-
tween AUCs in the prediction ability of the 28-day poor clinical
outcomes (Fig. 3). The test characteristics of lactate and procalci-
tonin at potential thresholds for poor clinical outcomes are pre-
sented in Table 4.4. Discussion
Based on the results of this study, none of the lactate and pro-
calcitonin values can be suggested alone to distinguish sepsis from
noninfectious SIRS in adult cancer patients to guide decision
making in the ED. This study sought to search for a screening test to
alert physicians regarding sepsis in cancer patients. But sensitivities
of lactate and procalcitonin decreased to nearly 70% at low
thresholds (1 mmol/L and 0.25 ng/mL, respectively). So, none of
them promised to serve as a rule-out test. Furthermore, none of
them was superior to the other or suggested utility in predicting
poor clinical outcomes.
Procalcitonin has been shown to be valuable in the diagnosis
and demonstration of the severity and prognosis of sepsis in liter-
ature.11e14 Lactate has also been suggested as a useful marker in the
diagnosis and prognosis of sepsis in many studies. However, cancer
patients were excluded in most of those studies.15,16 This study
investigated the diagnostic value of these markers in cancer pa-
tients where structural and functional immunosuppression pre-
sented together in the pathophysiology of sepsis. Although the
pathogenesis of lactate in the tumor tissue has been better un-
derstood, the pathogenesis of increased blood levels has not been
elucidated.17 In addition, lactate levels reported in septic cancer
patients were not different from the mean levels of septic patients
without malignancy in the literature.18,19 In this case, we believe
that our ﬁndings based on measured lactate levels in cancer pa-
tients in this study are valuable.
In their study investigating the use of lactate levels on sepsis
screening in ED patients without malignancy, Singer et al found
that lactate levels were similar between sepsis negative and
positive patients (1.35 mmol/L vs1.48 mmol/L), which is consis-
tent with our results. They also reported a lower AUC of 0.59
Table 3
The test characteristics of lactate and procalcitonin at potential thresholds for sepsis diagnosis.
Sensitivity % (95% CI) Speciﬁcity % (95%CI) (þ) LR (95% CI) () LR (95% CI)
Lactate > 1 mmol/L 86.36 (65.09e97.09) 28.12 (17.60e40.76) 1.20 (0.96e1.51) 0.48 (0.16e1.49)
Lactate > 2 mmol/L 37.04 (19.40e57.3) 79.66 (67.17e89.02) 1.82 (0.90e3.69) 0.79 (0.58e1.08)
Lactate > 4 mmol/L 22.73 (7.82e45.37) 95.31 (86.91e99.02) 4.85 (1.26e18.65) 0.81 (0.64e1.02)
Lactate > 2.98 mmol/L 36.36 (17.2e59.3) 90.62 (80.7e96.5) 3.88 (2.2e6.8) 0.70 (0.3e1.6)
Procalcitonin > 0.5 ng/mL 63.64 (40.66e82.80) 68.75 (55.94e79.76) 2.04 (1.26e3.30) 0.53 (0.30e0.94)
Procalcitonin > 2 ng/mL 36.36 (17.20e59.34) 85.94 (74.98e93.36) 2.59 (1.14e5.87) 0.74 (0.53e1.03)
Procalcitonin > 10 ng/mL 9.09 (1.12e29.16) 92.19 (82.7e97.41) 1.16 (0.24e5.57) 0.99 (0.85e1.15)
Procalcitonin > 0.8 ng/mL 63.64 (40.7e82.8) 76.56 (64.3e86.2) 2.72 (1.9e3.8) 0.47 (0.2e1)
CI: conﬁdence interval; LR: likelihood ratio.
Fig. 3. The comparison of ROC curves of serum lactate and procalcitonin levels for poor
clinical outcomes.
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sensitivity and 82.0% speciﬁcity at the limit of 2.0 mmol/L, and
emphasized the low sensitivity of the lactate levels in the diag-
nosis of sepsis.20 They reported a speciﬁcity close to our results
(95.3%) at the predictive value of 4.0 mmol/L in the same study,
and suggested that sepsis could not be excluded with normal
lactate levels.
The studies regarding the utility of lactate for diagnosis and
prognosis of sepsis in cancers patients have been limited in litera-
ture.9 Among 1129 septic cancer patients in an ICU, Hajjar et al
reported that the mortality was 28.7%, mean lactate levels were
different between surviving and dead patients (2.4 mmol/L vs
3.7 mmol/L), and found that the lactate levels could predict mor-
tality in multiple regression analysis.18 The lactate levels of sepsis
patients in our studywere lower than that. This result was expectedTable 4
The predictive values of lactate and procalcitonin at potential thresholds for poor clinica
Sensitivity % (95% CI) Speciﬁ
Lactate > 1 mmol/L 78.38 (61.79e90.17) 26.53
Lactate > 2 mmol/L 48.65 (31.92e65.60) 81.63
Lactate > 4 mmol/L 13.51 (4.54e28.77) 93.88
Lactate > 1.89 mmol/L 51.35 (34.40e68.10) 81.63
Procalcitonin > 0.5 ng/mL 43.24 (27.10e60.51) 63.27
Procalcitonin > 2 ng/mL 29.73 (15.87e46.98) 87.76
Procalcitonin > 10 ng/mL 13.51 (4.54e28.77) 95.92
Procalcitonin > 2.47 ng/mL 29.73 (15.90e47.00) 91.84
CI: conﬁdence interval; LR: likelihood ratio.since our sepsis positive patient group was composed of milder
forms since we did not group according to the severity of sepsis.
The other marker, assessed in this study was procalcitonin.
Procalcitonin has been suggested to be used in early diagnosis and
exclusion of infection in cancer patients in literature.21 However,
basal procalcitonin levels have been reported to be associated with
total and cancer mortality in a prospective cohort study that was in
the secondary analysis qualiﬁcation and included 3322 patients.22
Based on those ﬁndings, it has been proposed that procalcitonin
can exacerbate procarcinogenic inﬂammatory response, impair
anti-tumor immune mechanisms, and act as disease mediator in
cancer.22 However; if this assumption is correct, procalcitonin
levels would be expected to be high in all cancer patients. Yet,
normal procalcitonin levels weremeasured in half of the patients in
our study.
Although procalcitonin is accepted as a marker that can distin-
guish infectious and noninfectious processes in febrile neutropenic
patients,23 it showed the lowest diagnostic accuracy with an AUC of
0.71 in immunocompromised and neutropenic patients.24 In
detection of infection among febrile neutropenic patients with
solid tumors, its sensitivity was lower than our results (41.5%) and
the speciﬁcity was much higher (92.0%). Mortality was predicted
with 100% sensitivity and 83% speciﬁcity with 0.5 ng/mL procalci-
tonin level. Those ﬁndings were interpreted just as a support for
decision-making, not a guide.25 The current study suggested much
lower prognosis prediction as that study was conducted on only
febrile neutropenic patients.
The AUC for sepsis diagnosis was calculated in 66 patients as
0.75 for only SIRS criteria, 0.67 for only procalcitonin, and 0.92
when evaluated together in a study suggesting procalcitonin as a
probable indicator of early sepsis in SIRS patients without malig-
nancy in ED. The authors concluded that immediate bedside mea-
surement of procalcitonin in ED may be helpful for emergency
physicians.26 In another study comparing procalcitonin results and
judgment of emergency physician in detection of the presence of
infection in the ED, procalcitonin could diagnose the presence of
infection with 63.0% sensitivity and 79.0% speciﬁcity at the limit of
0.5 ng/mL in a population, one-third of which was composed ofl outcomes.
city % (95% CI) (þ) LR (95% CI) () LR (95% CI)
(14.95e41.08) 1.07 (0.84e1.35) 0.81 (0.38e1.76)
(67.98e91.24) 2.65 (1.35e5.21) 0.63 (0.45e0.88)
(83.13e98.72) 2.21 (0.56e8.65) 0.92 (0.80e1.07)
(68.00e91.20) 2.80 (2.00e3.90) 0.60 (0.30e1.20)
(48.29e76.58) 1.18 (0.70e1.98) 0.90 (0.63e1.28)
(75.23e95.37) 2.43 (0.99e5.96) 0.8 (0.63e1.01)
(86.02e99.50) 3.31 (0.68e16.13) 0.9 (0.78e1.04)
(80.40e97.70) 3.64 (2.20e6.00) 0.77 (0.30e2.00)
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36.0% and speciﬁcity increased to 93.0% at the limit of 2.0 ng/mL. In
addition, the superiority of procalcitonin levels over emergency
physician judgments could not be shown. The authors also pro-
posed the cutoff value of 0.2 ng/mL for emergency settings arguing
that much lower predictive values rather than the one in intensive
care units must be used in order for procalcitonin to be used as
early ﬁnding of infection.14 We did not calculate test characteristics
at the limit of 0.2 ng/mL, since the lower limit of the kit used in this
study was 0.25 ng/mL.
Debiane et al reported the AUC in cancer patients as 0.52 for
distinguishing sepsis from SIRS and as 0.77 for mortality and sug-
gested procalcitonin as a promising marker in terms of prognosis.9
In addition, they suggested that using procalcitonin together with
another infection marker may increase the diagnostic utility
considering that increased procalcitonin might arise from tumor
load. Freund et al8 similarly suggested that using lactate and pro-
calcitonin together would be more useful clinically instead of
comparing the markers in their study conducted with 462 partic-
ipants (84 of whichwere immunocompromised or cancer patients).
The authors reported the AUC as 0.565 and 0.748, respectively at
the predictive values of 1.4 mmol/L for lactate and 0.25 ng/mL for
procalcitonin in which ROC curve presents the best performance in
sepsis diagnosis. The authors found the AUC as 0.679 and 0.664,
respectively at markers' predictive values of 2.0 mmol/L and 0.8 ng/
mL in the study using the same deﬁnition for poor clinical outcome
as our group. The study determined that procalcitoninwas superior
in diagnosis of sepsis and lactate was superior in prediction of se-
vere sepsis. For prognostic values, they could increase the sensi-
tivity to 72.0% and negative predictive value to 88.0% even
evaluating that any of the markers were high. All these ﬁndings
supported our results suggesting that none of the markers are
sensitive enough to rely on.
In their prospective study Shomali et al27 found sensitivity as
67.0%, speciﬁcity as 62.0%, and the negative predictive value as
90.0% for procalcitonin value of 0.5 ng/mL in diagnosis of bacter-
emia. The striking feature of that study was the detection of
signiﬁcantly higher procalcitonin levels in patients with metastatic
cancer compared to the levels in non-metastatic patients.27 We
could not analyze the patients in cancer stage subgroups. In this
context, it is possible that procalcitonin may suggest higher utility
in a non-metastatic cancer population.
When we compared lactate and procalcitonin, we observed no
difference in the diagnosis of sepsis and prediction of poor out-
comes. In addition, they had no sufﬁcient diagnostic and prognostic
value alone in distinguishing cancer-induced inﬂammatory
response ﬁndings, clinical sepsis in the early period to guide ED
management of cancer patients. Although the lactate levels higher
than 1 mmol/L did not have ideal sensitivity in SIRS patients with
cancer, we believe that those levels were sufﬁcient to draw atten-
tion of emergency physicians to sepsis possibility to initiate early
treatment.
4.1. Limitations
The small sample size may have limited to reach statistical
signiﬁcance in this single center study. Because of time restriction
and overcrowding in the ED, there might be some patients over-
looked. The authors were aware that SIRS is not a reliable criterion
in cancer patients.28 Nevertheless, it was preferred for homoge-
neity for inclusion criteria to provide reliable comparison among
studies.29
A single measurement of lactate and procalcitonin might
have also contributed to the interpretation of the results. Only
one measurement was performed in this study in order toinvestigate a biomarker at triage as a strong clue for sepsis in
cancer patients.
The researcher who decided the presence of infection was not
blind to the procalcitonin levels. This might have led to a bias in
sepsis diagnosis or in the differentiation of positive and negative
groups. Lack of a gold standard in the determination of bacteremia
and infection, low rates of blood culture results, and the possibility
of unnoticed occult infection foci might also cause an incorrect
classiﬁcation of patients.
Medications used by patients in the study group were not
evaluated in terms of the possible cause of lactate elevation. In this
study, 16.0% of the patients were diabetic and might be using
metformin. However, the literature has supported that prescribed
doses of metformin do not lead to signiﬁcant lactate elevation.30
The markers could not be assessed in the subgroup analysis due
to the lack of data in patients' tumor stage. The subgroup analyses
may provide more valuable information on the usefulness of
markers in cancer patients, since both procalcitonin and lactate are
markers that may be affected by tumor stage and tumor
aggressiveness.
5. Conclusions
The results of this study revealed that the lactate and procalci-
tonin levels cannot be used reliably in differentiating sepsis from
noninfectious SIRS or predicting clinical outcomes in cancer pa-
tients in the ED. Considering that cancer patients are at high risk for
sepsis and poor clinical outcomes, further extensive studies to
assess cancer stages, sepsis severity classes, and early diagnostic
biomarkers should be conducted.
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